Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Vonaprument · ANX-007

Monoclonal antibody · Inhibitor of complement component C3 (C3) · developed by Annexon

Phase 3 Most advanced trial

ANNX Developer

2 Registered trials

What is Vonaprument?

Vonaprument (ANX007) is an antibody administered by intravitreal injection for geographic atrophy, a progressive form of age-related macular degeneration.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ANX-007
Drug type: Monoclonal antibody
Targets: complement component C3 (C3)
Mechanism: Inhibitor of complement component C3 (C3)
Pathways: complement cascade
Therapy area: Ophthalmology
Developer: Annexon, Inc. (ANNX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 9HLL22LOX6

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06510816	Phase 3	Geographic Atrophy	Active not recruiting	ANNX
NCT04656561	Phase 2	Geographic Atrophy	Completed	ANNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Geographic Atrophy

More from Annexon

ANX009 Phase 1 ANX105 Phase 1 ANX1502 Phase 1 Tanruprubart Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ANNX page.

Follow ANNX, the company behind Vonaprument

See ANNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANNX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z